Clinical Trial Update: Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy [Phase 3]

View source ↗

Summary

Phase 3 safety and tolerability trial of rifaximin in participants with a history of hepatic encephalopathy has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Hepatic Encephalopathy | Phase 3 | Status: COMPLETED | Results posted: 2019-08-14